Febuxostat ameliorates muscle degeneration and movement disorder of the dystrophin mutant model in Caenorhabditis elegans

Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509–517. https://doi.org/10.1016/0092-8674(87)90504-6 Erturk O, Bilguvar K, Korkmaz B, Bayri Y, Bayrakli F, Arlier Z, Ozturk AK, Yalcinkaya C, Tuysuz B, State MW, Gunel M (2010) A patient with Duchenne muscular dystrophy and autism demonstrates a hemizygous deletion affecting Dystrophin. Am J Med Genet A 152A:1039–1042. https://doi.org/10.1002/ajmg.a.33312 Starnes JR, Crum K, George-Durrett K, Godown J, Parra DA, Markham LW, Soslow JH (2022) Novel cardiac imaging risk score for mortality prediction in duchenne muscular dystrophy. Pediatr Cardiol. https://doi.org/10.1007/s00246-022-03040-6 Szabo SM, Klimchak AC, Qian C, Iannaccone S, Popoff E, Gooch KL (2022) Characterizing the occurrence of key clinical milestones in Duchenne muscular dystrophy in the united states using real-world data. J Neuromuscul Dis 9:689–699. https://doi.org/10.3233/JND-220816 Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016:CD003725. https://doi.org/10.1002/14651858.CD003725.pub4 Webster C, Blau HM (1990) Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet 16:557–565. https://doi.org/10.1007/BF01233096 Warren GL, Hayes DA, Lowe DA, Prior BM, Armstrong RB (1993) Materials fatigue initiates eccentric contraction-induced injury in rat soleus muscle. J Physiol 464:477–489. https://doi.org/10.1113/jphysiol.1993.sp019646 Ljubicic V, Jasmin BJ (2013) AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy. Trends Mol Med 19:614–624. https://doi.org/10.1016/j.molmed.2013.07.002 Lim KRQ, Woo S, Melo D, Huang Y, Dzierlega K, Shah MNA, Aslesh T, Roshmi RR, Echigoya Y, Maruyama R, Moulton HM, Yokota T (2022) Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2112546119 Yoshina S, Izuhara L, Kamatani N, Mitani S (2022) Regulation of aging by balancing mitochondrial function and antioxidant levels. J Physiol Sci 72:28. https://doi.org/10.1186/s12576-022-00853-1 Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA (2005) Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 76:1835–1847. https://doi.org/10.1016/j.lfs.2004.10.031 Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77:71–94 Gengyo-Ando K, Mitani S (2000) Characterization of mutations induced by ethyl methanesulfonate, UV, and trimethylpsoralen in the nematode Caenorhabditis elegans. Biochem Biophys Res Commun 269:64–69. https://doi.org/10.1006/bbrc.2000.2260 Gengyo-Ando K, Kuroyanagi H, Kobayashi T, Murate M, Fujimoto K, Okabe S, Mitani S (2007) The SM protein VPS-45 is required for RAB-5-dependent endocytic transport in Caenorhabditis elegans. EMBO Rep 8:152–157. https://doi.org/10.1038/sj.embor.7400882 Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153:228–239. https://doi.org/10.1016/j.cell.2013.02.035 Gaud A, Simon JM, Witzel T, Carre-Pierrat M, Wermuth CG, Ségalat L (2004) Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord 14:365–370. https://doi.org/10.1016/j.nmd.2004.02.011 Oh KH, Kim H (2013) Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy. Proc Natl Acad Sci USA 110:19024–19029. https://doi.org/10.1073/pnas.1308866110 Hewitt JE, Pollard AK, Lesanpezeshki L, Deane CS, Gaffney CJ, Etheridge T, Szewczyk NJ, Vanapalli SA (2018) Muscle strength deficiency and mitochondrial dysfunction in a muscular dystrophy model of Caenorhabditis elegans and its functional response to drugs. Dis Model Mech. https://doi.org/10.1242/dmm.036137 Brouilly N, Lecroisey C, Martin E, Pierson L, Mariol MC, Qadota H, Labouesse M, Streichenberger N, Mounier N, Gieseler K (2015) Ultra-structural time-course study in the C. elegans model for Duchenne muscular dystrophy highlights a crucial role for sarcomere-anchoring structures and sarcolemma integrity in the earliest steps of the muscle degeneration process. Hum Mol Genet 24:6428–6445. https://doi.org/10.1093/hmg/ddv353 Benian GM, Epstein HF (2011) Caenorhabditis elegans muscle: a genetic and molecular model for protein interactions in the heart. Circ Res 109:1082–1095. https://doi.org/10.1161/CIRCRESAHA.110.237685 Matsunaga Y, Hwang H, Franke B, Williams R, Penley M, Qadota H, Yi H, Morran LT, Lu H, Mayans O, Benian GM (2017) Twitchin kinase inhibits muscle activity. Mol Biol Cell 28:1591–1600. https://doi.org/10.1091/mbc.E16-10-0707 Prosser BL, Ward CW, Lederer WJ (2011) X-ROS signaling: rapid mechano-chemo transduction in heart. Science 333:1440–1445. https://doi.org/10.1126/science.1202768 Tidball JG (1985) Wehling-Henricks M (2007) The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 102:1677–1686. https://doi.org/10.1152/japplphysiol.01145.2006 Lawler JM (2011) Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy. J Physiol 589:2161–2170. https://doi.org/10.1113/jphysiol.2011.207456 Ellwood RA, Hewitt JE, Torregrossa R, Philp AM, Hardee JP, Hughes S, van de Klashorst D, Gharahdaghi N, Anupom T, Slade L, Deane CS, Cooke M, Etheridge T, Piasecki M, Antebi A, Lynch GS, Philp A, Vanapalli SA, Whiteman M, Szewczyk NJ (2021) Mitochondrial hydrogen sulfide supplementation improves health in the. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2018342118 Higashitani A, Teranishi M, Nakagawa Y, Itoh Y, Sudevan S, Szewczyk NJ, Kubota Y, Abe T, Kobayashi T (2023) Increased mitochondrial Ca. FASEB J 37:e22851. https://doi.org/10.1096/fj.202201489RR Escolar DM, Scacheri CG (2001) Pharmacologic and genetic therapy for childhood muscular dystrophies. Curr Neurol Neurosci Rep 1:168–174. https://doi.org/10.1007/s11910-001-0013-y Hinton VJ, Fee RJ, Goldstein EM, De Vivo DC (2007) Verbal and memory skills in males with Duchenne muscular dystrophy. Dev Med Child Neurol 49:123–128. https://doi.org/10.1111/j.1469-8749.2007.00123.x Lidov HG, Byers TJ, Watkins SC, Kunkel LM (1990) Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. Nature 348:725–728. https://doi.org/10.1038/348725a0 Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L (2006) Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 45:821–841. https://doi.org/10.2165/00003088-200645080-00005 Jiménez ML, Puig JG, Mateos FA, Ramos TH, Castroviejo IP, Vázquez JO (1989) Hypoxanthine and xanthine transport through the blood-brain barrier in hypoxanthine phosphoribosyltransferase (HPRT) deficiency. Adv Exp Med Biol 253A:173–179. https://doi.org/10.1007/978-1-4684-5673-8_28 Johnson TA, Jinnah HA, Kamatani N (2019) Shortage of cellular ATP as a cause of diseases and strategies to enhance ATP. Front Pharmacol 10:98. https://doi.org/10.3389/fphar.2019.00098